AXON Axovant Sciences Ltd. Common Sh

15.06
-1  -3%
Previous Close 15.60
Open 15.60
Price To book 9.29
Market Cap 1.49B
Shares 99,161,000
Volume 379,128
Short Ratio 8.78
Av. Daily Volume 361,608

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2b data due 4Q 2017
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Full study to be completed mid-2017. Phase 3 trial to be initiated 2H 2017.
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 3 data are due 3Q 2017.
Intepirdine - MINDSET
Alzheimer's disease

Latest News

  1. Axovant Sciences to Present at Upcoming Scientific Meetings
  2. Axovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference
  3. Is the Options Market Predicting a Spike in Axovant Sciences (AXON) Stock?
  4. Axovant Sciences to Present at Upcoming Investor Conferences
  5. 3 Biotech Long Shots: Boom Or Bust?
  6. PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer
  7. AXOVANT SCIENCES LTD. Financials
  8. Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?
  9. AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
  10. Axovant reports 3Q loss
  11. Axovant reports 3Q loss
  12. Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016
  13. The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
  14. Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
  15. AXOVANT SCIENCES LTD. Files SEC form 8-K, Other Events
  16. Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients
  17. Axovant Rival's Alzheimer Drug Fails Study
  18. AXOVANT SCIENCES LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
  19. Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital
  20. Axovant Sciences to Present at Upcoming Investor Conferences